Clinical Trials Browser

Phase 4 × INDUSTRY × Endocrine × Clear all

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT05631795 2025-12-03

ALPINIST

Phase 4 Completed

40 enrolled

Endocrine

Multiple Endocrine Neoplasia Type 1

NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Phase 4 Completed

61 enrolled 9 charts

EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Phase 4 Completed

42 enrolled 11 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT00681187 2019-11-22

SAPHE

Phase 4 Completed

26 enrolled 18 charts

Endocrine

Neuroendocrine Tumour With Carcinoid Symptoms

NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Phase 4 Completed

106 enrolled 26 charts

EndocrineGastrointestinalNET

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

NCT01595009 2018-11-29

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Phase 4 Completed

246 enrolled 16 charts

EndocrineNET

Neuroendocrine Tumors

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Phase 4 Completed

20 enrolled

CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

Clinical Trials

ODYSSEY

ALPINIST

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

SAPHE

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly